Use of activated coagulation factor Vll for treating thrombolytic therapy-induced major bleedings

摘要

Major bleedings induced by thrombolytic/fibrinolytic therapy, including intracranial haemorrhages, are treated by administering to a subject suffering from such bleedings an effective amount of activated coagulation factor VII (VIIa) or a functional derivative thereof.